Galectin Therapeutics (GALT) Amortization of Deferred Charges (2018 - 2026)

Galectin Therapeutics' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $156000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 55.04% year-over-year to $156000.0; the TTM figure through Mar 2026 stood at $903000.0 (down 27.12% YoY), while the FY2025 annual figure was $1.1 million, down 0.55% from the prior year.
• Amortization of Deferred Charges was $156000.0 for Q1 2026 at Galectin Therapeutics, down from $183000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $352000.0 in Q4 2024 to a low of $78000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $203352.9 across 5 years, with a median of $192000.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Amortization of Deferred Charges soared 972.73% in 2022, then plunged 55.04% in 2026.
• A 5-year view of Amortization of Deferred Charges shows it stood at $134000.0 in 2022, then soared by 43.28% to $192000.0 in 2023, then soared by 83.33% to $352000.0 in 2024, then slumped by 48.01% to $183000.0 in 2025, then dropped by 14.75% to $156000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $156000.0 (Q1 2026), $183000.0 (Q4 2025), and $215000.0 (Q3 2025), per Business Quant data.